Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

PMID:
24638849
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.

Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M.

Am J Clin Oncol. 2013 Oct;36(5):436-42. doi: 10.1097/COC.0b013e3182568f7a.

PMID:
22781385
[PubMed - indexed for MEDLINE]
3.
4.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.

J Clin Oncol. 2006 Oct 20;24(30):4895-900. Epub 2006 Sep 25.

PMID:
17001071
[PubMed - indexed for MEDLINE]
Free Article
5.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
[PubMed - indexed for MEDLINE]
6.

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.

Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M.

Springerplus. 2014 Oct 1;3:577. doi: 10.1186/2193-1801-3-577. eCollection 2014.

PMID:
25332877
[PubMed]
Free PMC Article
7.

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.

Oncologist. 2007 Sep;12(9):1035-43.

PMID:
17914073
[PubMed - indexed for MEDLINE]
Free Article
8.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.

Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30.

PMID:
23722472
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
[PubMed - indexed for MEDLINE]
10.

Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.

Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M, Edwards S.

Support Care Cancer. 2013 Jun;21(6):1557-60. doi: 10.1007/s00520-012-1694-2. Epub 2013 Jan 19.

PMID:
23334521
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI.

Lancet Oncol. 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16.

PMID:
23684411
[PubMed - indexed for MEDLINE]
12.

Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.

Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R.

Clin Oncol (R Coll Radiol). 2013 Apr;25(4):217-26. doi: 10.1016/j.clon.2012.11.004. Epub 2012 Dec 6.

PMID:
23219232
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.

Clin Ther. 2005 Aug;27(8):1295-310.

PMID:
16199254
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.

Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.

Oncologist. 2006 Jul-Aug;11(7):841-8.

PMID:
16880243
[PubMed - indexed for MEDLINE]
Free Article
15.

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.

Ann Oncol. 2007 Jul;18(7):1165-71. Epub 2007 Apr 17. Erratum in: Ann Oncol. 2008 Mar;19(3):601.

PMID:
17442659
[PubMed - indexed for MEDLINE]
Free Article
16.

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X.

BMC Cancer. 2011 Sep 22;11:403. doi: 10.1186/1471-2407-11-403.

PMID:
21936956
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.

J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e.

PMID:
18317064
[PubMed - indexed for MEDLINE]
18.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632
[PubMed - indexed for MEDLINE]
Free Article
19.

The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.

Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.

Calcif Tissue Int. 2007 Nov;81(5):341-51. Epub 2007 Sep 18.

PMID:
17874331
[PubMed - indexed for MEDLINE]
20.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.

Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.

PMID:
23799855
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk